Research programme: cancer therapeutics - Owkin
Latest Information Update: 06 Nov 2024
Price :
$50 *
At a glance
- Originator Owkin
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Bladder cancer; Diffuse large B cell lymphoma; Mesothelioma; Ovarian cancer
Most Recent Events
- 16 Oct 2024 Early research in Bladder cancer in USA (unspecified route) prior to October 2024 (Owkin pipeline; October 2024)
- 16 Oct 2024 Early research in Diffuse large B cell lymphoma in USA (unspecified route) prior to October 2024 (Owkin pipeline; October 2024)
- 16 Oct 2024 Early research in Mesothelioma in USA (unspecified route) prior to October 2024 (Owkin pipeline; October 2024)